Table of Contents
1. REPORT PROLOGUE
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Primary Research
3.3. Secondary Research
3.4. Market Size Estimation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Porter’s Five Forces Analysis
5.1.1. Bargaining Power of Suppliers
5.1.2. Bargaining Power of Buyers
5.1.3. Threat of New Entrants
5.1.4. Threat of Substitutes
5.1.5. Intensity of Rivalry
5.2. Value Chain Analysis
6. GLOBAL SCHIZOPHRENIA MARKET, BY TYPE
6.1. Overview
6.2. Paranoid schizophrenia
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
6.3. Hebephrenic schizophrenia
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
6.4. Catatonic schizophrenia
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
6.5. Undifferentiated schizophrenia
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
7. GLOBAL SCHIZOPHRENIA MARKET, BY TREATMENT
7.1. Overview
7.2. Second-Generation Antipsychotics
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
7.2.1. Risperdal (Risperidone)
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
7.2.2. Invega (Paliperidone)
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
7.2.3. Zyprexa (Olanzapine)
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
7.2.4. Geodon (Ziprasidone)
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
7.2.5. Seroquel (Quetiapine)
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
7.2.6. Latuda (Lurasidone)
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
7.2.7. Others
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
7.3. Third-Generation Antipsychotics
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
7.4. Others
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
8. GLOBAL SCHIZOPHRENIA MARKET, BY ROUTE OF ADMINISTRATION
8.1. Overview
8.2. Oral
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
8.3. Injectables
Market Estimates & Forecast, by Region, 2022-2030
Market Estimates & Forecast, by Country, 2022-2030
9. GLOBAL SCHIZOPHRENIA MARKET, BY REGION
9.1. Overview
9.2. Americas
9.2.1. North America
9.2.1.1. US
9.2.1.2. Canada
9.2.2. Latin America
9.3. Europe
9.3.1. Western Europe
9.3.1.1. Germany
9.3.1.2. France
9.3.1.3. Italy
9.3.1.4. Spain
9.3.1.5. UK
9.3.1.6. Rest of Western Europe
9.3.2. Eastern Europe
9.4. Asia-Pacific
9.4.1. Japan
9.4.2. China
9.4.3. India
9.4.4. Australia
9.4.5. South Korea
9.4.6. Rest of Asia-Pacific
9.5. Middle East & Africa
9.5.1. Middle East
9.5.2. Africa
10. COMPANY LANDSCAPE
10.1. Overview
10.2. Competitive Analysis
10.3. Market Share Analysis
10.4. Major Growth Strategy in the Global Schizophrenia Market
10.5. Competitive Benchmarking
10.6. Leading Players in Terms of Number of Developments in the Global Schizophrenia Market
10.7. Key developments and Growth Strategies
10.7.1. Product Launch/Service Deployment
10.7.2. Mergers and Acquisitions
10.7.3. Joint Ventures
10.8. Major Players Financial Matrix & Market Ratio
10.8.1. Sales & Operating Income 2022
10.8.2. Major Players R&D Expenditure 2022
10.9. Major Players Capital Market Ratio
11. COMPANY PROFILES
11.1. Johnson & Johnson
11.1.1. Company Overview
11.1.2. Product Overview
11.1.3. Financial Overview
11.1.4. Key Developments
11.1.5. SWOT Analysis
11.1.6. Key Strategies
11.2. Bristol-Myers Squibb and Company/ Otsuka Pharmaceuticals
11.2.1. Company Overview
11.2.2. Product Overview
11.2.3. Financial Overview
11.2.4. Key Developments
11.2.5. SWOT Analysis
11.2.6. Key Strategies
11.3. AstraZeneca
11.3.1. Company Overview
11.3.2. Product Overview
11.3.3. Financial Overview
11.3.4. Key Developments
11.3.5. SWOT Analysis
11.3.6. Key Strategies
11.4. Eli Lilly
11.4.1. Company Overview
11.4.2. Product Overview
11.4.3. Financial Overview
11.4.4. Key Developments
11.4.5. SWOT Analysis
11.4.6. Key Strategies
11.5. Alkermes
11.5.1. Company Overview
11.5.2. Product Overview
11.5.3. Financial Overview
11.5.4. Key Developments
11.5.5. SWOT Analysis
11.5.6. Key Strategies
11.6. Sumitomo Dainippon Pharma
11.6.1. Company Overview
11.6.2. Product Overview
11.6.3. Financial Overview
11.6.4. Key Developments
11.6.5. SWOT Analysis
11.6.6. Key Strategies
11.7. Pfizer
11.7.1. Company Overview
11.7.2. Product Overview
11.7.3. Financial Overview
11.7.4. Key Developments
11.7.5. SWOT Analysis
11.7.6. Key Strategies
11.8. Vanda Pharmaceuticals
11.8.1. Company Overview
11.8.2. Product Overview
11.8.3. Financial Overview
11.8.4. Key Developments
11.8.5. SWOT Analysis
11.8.6. Key Strategies
11.9. Allergan/ Geodon Ritcher
11.9.1. Company Overview
11.9.2. Product Overview
11.9.3. Financial Overview
11.9.4. Key Developments
11.9.5. SWOT Analysis
11.9.6. Key Strategies
11.10. Others
12. APPENDIX
12.1. References
12.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL SCHIZOPHRENIA MARKET SYNOPSIS, 2022-2030
TABLE 2 GLOBAL SCHIZOPHRENIA MARKET ESTIMATES & FORECAST, 2022-2030 (USD MILLION)
TABLE 3 GLOBAL SCHIZOPHRENIA MARKET, BY TYPE, 2022-2030 (USD MILLION)
TABLE 4 GLOBAL SCHIZOPHRENIA MARKET, BY TREATMENT, 2022-2030 (USD MILLION)
TABLE 5 GLOBAL SCHIZOPHRENIA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
TABLE 6 GLOBAL SCHIZOPHRENIA MARKET, BY REGION, 2022-2030 (USD MILLION)
TABLE 7 NORTH AMERICA: SCHIZOPHRENIA MARKET, BY TYPE, 2022-2030 (USD MILLION)
TABLE 8 NORTH AMERICA: SCHIZOPHRENIA MARKET, BY TREATMENT, 2022-2030 (USD MILLION)
TABLE 9 NORTH AMERICA: SCHIZOPHRENIA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
TABLE 10 US: SCHIZOPHRENIA MARKET, BY TYPE, 2022-2030 (USD MILLION)
TABLE 11 US: SCHIZOPHRENIA MARKET, BY TREATMENT, 2022-2030 (USD MILLION)
TABLE 12 US: SCHIZOPHRENIA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
TABLE 13 CANADA: SCHIZOPHRENIA MARKET, BY TYPE, 2022-2030 (USD MILLION)
TABLE 14 CANADA: SCHIZOPHRENIA MARKET, BY TREATMENT, 2022-2030 (USD MILLION)
TABLE 15 CANADA: SCHIZOPHRENIA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
TABLE 16 LATIN AMERICA: SCHIZOPHRENIA MARKET, BY TYPE, 2022-2030 (USD MILLION)
TABLE 17 LATIN AMERICA: SCHIZOPHRENIA MARKET, BY TREATMENT, 2022-2030 (USD MILLION)
TABLE 18 LATIN AMERICA: SCHIZOPHRENIA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
TABLE 19 EUROPE: SCHIZOPHRENIA MARKET, BY TYPE, 2022-2030 (USD MILLION)
TABLE 20 EUROPE: SCHIZOPHRENIA MARKET, BY TREATMENT, 2022-2030 (USD MILLION)
TABLE 21 EUROPE: SCHIZOPHRENIA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
TABLE 22 WESTERN EUROPE: SCHIZOPHRENIA MARKET, BY TYPE, 2022-2030 (USD MILLION)
TABLE 23 WESTERN EUROPE: SCHIZOPHRENIA MARKET, BY TREATMENT, 2022-2030 (USD MILLION)
TABLE 24 WESTERN EUROPE: SCHIZOPHRENIA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
TABLE 25 EASTERN EUROPE: SCHIZOPHRENIA MARKET, BY TYPE, 2022-2030 (USD MILLION)
TABLE 26 EASTERN EUROPE: SCHIZOPHRENIA MARKET, BY TREATMENT, 2022-2030 (USD MILLION)
TABLE 27 EASTERN EUROPE: SCHIZOPHRENIA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
TABLE 28 ASIA-PACIFIC: SCHIZOPHRENIA MARKET, BY TYPE, 2022-2030 (USD MILLION)
TABLE 29 ASIA-PACIFIC: SCHIZOPHRENIA MARKET, BY TREATMENT, 2022-2030 (USD MILLION)
TABLE 30 ASIA-PACIFIC: SCHIZOPHRENIA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA: SCHIZOPHRENIA MARKET, BY TYPE, 2022-2030 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA: SCHIZOPHRENIA MARKET, BY TREATMENT, 2022-2030 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA: SCHIZOPHRENIA MARKET, BY ROUTE OF ADMINISTRATION, 2022-2030 (USD MILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL SCHIZOPHRENIA MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL SCHIZOPHRENIA MARKET
FIGURE 4 GLOBAL SCHIZOPHRENIA MARKET SHARE, BY TYPE, 2022 (%)
FIGURE 5 GLOBAL SCHIZOPHRENIA MARKET SHARE, BY TREATMENT, 2022 (%)
FIGURE 6 GLOBAL SCHIZOPHRENIA MARKET SHARE, BY ROUTE OF ADMINISTRATION, 2022 (%)
FIGURE 7 GLOBAL SCHIZOPHRENIA MARKET SHARE, BY REGION, 2022 (%)
FIGURE 8 AMERICAS: SCHIZOPHRENIA MARKET SHARE BY REGION, 2022 (%)
FIGURE 9 NORTH AMERICA: SCHIZOPHRENIA MARKET SHARE, BY COUNTRY, 2022 (%)
FIGURE 10 EUROPE: SCHIZOPHRENIA MARKET SHARE, BY REGION, 2022 (%)
FIGURE 11 WESTERN EUROPE: SCHIZOPHRENIA MARKET SHARE, BY COUNTRY, 2022 (%)
FIGURE 12 ASIA-PACIFIC: SCHIZOPHRENIA MARKET SHARE, BY COUNTRY, 2022 (%)
FIGURE 13 MIDDLE EAST & AFRICA: SCHIZOPHRENIA MARKET SHARE, BY COUNTRY, 2022 (%)
FIGURE 14 GLOBAL SCHIZOPHRENIA MARKET: COMPANY SHARE ANALYSIS, 2022 (%)
FIGURE 15 JOHNSON & JOHNSON: KEY FINANCIALS
FIGURE 16 JOHNSON & JOHNSON: SEGMENTAL REVENUE
FIGURE 17 JOHNSON & JOHNSON: REGIONAL REVENUE
FIGURE 18 ASTRAZENECA: KEY FINANCIALS
FIGURE 19 ASTRAZENECA: SEGMENTAL REVENUE
FIGURE 20 ASTRAZENECA: REGIONAL REVENUE
FIGURE 21 ELI LILLY: KEY FINANCIALS
FIGURE 22 ELI LILLY: SEGMENTAL REVENUE
FIGURE 23 ELI LILLY: REGIONAL REVENUE
FIGURE 24 ALKERMES: KEY FINANCIALS
FIGURE 25 ALKERMES: SEGMENTAL REVENUE
FIGURE 26 ALKERMES: REGIONAL REVENUE
FIGURE 27 SUMITOMO DAINIPPON PHARMA: KEY FINANCIALS
FIGURE 28 SUMITOMO DAINIPPON PHARMA: SEGMENTAL REVENUE
FIGURE 29 SUMITOMO DAINIPPON PHARMA: REGIONAL REVENUE
FIGURE 30 PFIZER: KEY FINANCIALS
FIGURE 31 PFIZER: SEGMENTAL REVENUE
FIGURE 32 PFIZER: REGIONAL REVENUE
FIGURE 33 VANDA PHARMACEUTICALS: KEY FINANCIALS
FIGURE 34 VANDA PHARMACEUTICALS: SEGMENTAL REVENUE
FIGURE 35 VANDA PHARMACEUTICALS: REGIONAL REVENUE
FIGURE 36 ALLERGAN/ GEODON RITCHER: KEY FINANCIALS
FIGURE 37 ALLERGAN/ GEODON RITCHER: SEGMENTAL REVENUE
FIGURE 38 ALLERGAN/ GEODON RITCHER: REGIONAL REVENUE
